Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

12.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.2K
Genetic Screens02:46

Genetic Screens

5.8K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

26
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

51
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
51

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Successful use of upadacitinib in refractory bilateral rheumatoid pleural effusion.

Rheumatology (Oxford, England)·2026
Same author

A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations.

Clinical lung cancer·2026
Same author

[Update on the regression grading of non-small cell lung cancer].

Pathologie (Heidelberg, Germany)·2026
Same author

Translucency, opalescence and fluorescence of human teeth in relation to the storage time after extraction.

Journal of dentistry·2025
Same author

Effect of Cleaning Protocols on Surface Roughness of Current Polymeric Denture Materials.

Journal of functional biomaterials·2025
Same author

Current practice of pathologic response assessment following chemoimmunotherapy for non-small cell lung cancer (NSCLC) in Germany: first real-world data from the multicentre Re-GraDE study.

Histopathology·2025

Related Experiment Video

Updated: Feb 24, 2026

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

11.0K

How Phenotypic Screening Influenced Drug Discovery: Lessons from Five Years of Practice.

Dorothea Haasen1, Ulrich Schopfer1, Christophe Antczak2

  • 11 Novartis Institutes for BioMedical Research (NIBR) , Chemical Biology and Therapeutics (CBT), Basel, Switzerland .

Assay and Drug Development Technologies
|August 12, 2017
PubMed
Summary

Phenotypic screening, a drug discovery trend, faces challenges despite promises of finding novel drugs. Lessons learned are shaping future drug discovery approaches, integrating phenotypic concepts into target-based strategies.

Keywords:
phenotypicphenotypic strategyscreening strategytarget based strategy

More Related Videos

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.6K
High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

18.2K

Related Experiment Videos

Last Updated: Feb 24, 2026

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

11.0K
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.6K
High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

18.2K

Area of Science:

  • Drug discovery and development
  • Pharmaceutical sciences
  • Biotechnology

Background:

  • Phenotypic screening has gained prominence since 2011 for discovering first-in-class drugs.
  • This approach, while promising, has presented significant challenges in pharmaceutical research.
  • Recent years have seen limited success stories, prompting reevaluation of investments.

Purpose of the Study:

  • To outline key success factors and challenges encountered in phenotypic screening.
  • To describe how phenotypic screening efforts have influenced overall drug discovery strategies.
  • To predict the future integration of phenotypic screening concepts into other approaches.

Main Methods:

  • Review and analysis of lessons learned from phenotypic screening initiatives.
  • Description of the impact of phenotypic screening on general drug discovery methodologies.
  • Forecasting future trends in pharmaceutical research and development.

Main Results:

  • Identification of critical success factors and persistent challenges in phenotypic screening.
  • Demonstration of how phenotypic screening has adapted and refined drug discovery processes.
  • Insights into the evolving landscape of drug discovery strategies.

Conclusions:

  • Phenotypic screening, despite its challenges, offers valuable lessons for drug discovery.
  • The principles of phenotypic screening are expected to be integrated into target-based approaches.
  • This integration will ensure the continued influence of phenotypic screening concepts in the pharmaceutical industry.